Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of QL1706 in recurrent or metastatic cervical cancer
CTR20213038Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in cervical cancer (mCC), sponsored by Qilu Pharmaceutical. Started Dec 2021; status: completed.
02
Drugs
QL1706
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on CTR20213038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213038.